TargetBeta
EPAS1
endothelial PAS domain protein 1 · also MOP2, PASD2, HIF2A, HLF · Basic helix-loop-helix proteins
2 programs in company-led studies act on EPAS1, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| belzutifanrule | Merck | phase 3 | 2415 running | – | ChEMBL |
| casdatifanrule | Arcus Biosciences | phase 3 | 94 running | – | the studies' text |
Conditions their studies are in
- Carcinoma, Renal Cell, 2 programs
- Breast Neoplasms, 1 program
- Clear-cell metastatic renal cell carcinoma, 1 program
- Neoplasms, 1 program
- Pheochromocytoma, 1 program
- von Hippel-Lindau Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 29, 2027casdatifan · Arcus Biosciences · phase 3 · NCT07000149
- Feb 26, 2027belzutifan · Merck · phase 3 · NCT03634540
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.